Fundraising Fox
Citryll
Oss, NL · Founded 2015 · 38 employees on LinkedIn · 8 known investors
Find your way into Citryll
Each arrow is one introduction. Sign up to fill in the first one.
Ask Daniela Couto to introduce you to Renato Chirivi
You →Daniela · together at Citryll →Renato
Sign up to find every way you can get introduced to Citryll
- Your email: who you already know at Citryll, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Citryll team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones. The company is advancing clinical programs in immune-mediated inflammatory diseases, with a current focus on rheumatoid arthritis and hidradenitis suppurativa.
Founders & leadership
Citryll was founded in 2015 by Renato Chirivi.
Board
Investors · 8
How we know: the company's own site · BioGeneration Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: Pureos Bioventures's portfolio page · the company's own site · funding news · Not right? Tell us
How we know: the company's own site · Seventure Partners's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: the company's own site · a partner's Signal profile · funding news · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: Novartis Venture Fund's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$92.5M disclosed across 1 round · 2024
- $92.5MSeries BDec 2024 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Citryll do?
- Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones. The company is advancing clinical programs in immune-mediated inflammatory diseases, with a current focus on rheumatoid arthritis and hidradenitis suppurativa.
- Who founded Citryll?
- Citryll was founded by Renato Chirivi in 2015.
- Who are Citryll's investors?
- Citryll's investors include BioGeneration Ventures, Pureos Bioventures, Seventure Partners, Forbion, Johnson & Johnson Innovation – JJDC, BOM, Curie Capital, Novartis Venture Fund.
- How much funding has Citryll raised?
- Citryll has disclosed $92.5M raised across 1 round.
- Where is Citryll headquartered?
- Citryll is headquartered in Oss, NL.